Veraxa Biotech Holding AG (VRXA) Common Equity (2024 - 2025)
Veraxa Biotech Holding AG's (VRXA) quarterly Common Equity came in at -$364747.3 in Q4 2025, down 101.03% year-on-year from $35.4 million in Q4 2024, and down 101.03% on a QoQ basis from $35.4 million in Q4 2024.
Veraxa Biotech Holding AG (VRXA) Common Equity (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXA) has 2 years of Common Equity data on file, last reported at -$364747.3 in Q4 2025.
- On a quarterly basis, Common Equity fell 101.03% year-over-year to -$364747.3 in Q4 2025; TTM through Dec 2025 was -$364747.3, a 101.03% decrease from a year earlier, with the FY2025 full-year figure at -$364747.3, down 101.03% from the prior year.
- Common Equity for Q4 2025 stood at -$364747.3, down from $35.4 million in the prior quarter.
- Over the last five years, Common Equity for VRXA reached as high as $35.4 million in Q4 2024 and fell as low as -$364747.3 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -364,747.27 |
| Dec 31, 2024 | 35.45 Mn |